 Enhanced percutaneous absorption novel topical cyclosporin formulation assessment immunosuppressive activity successful topical cyclosporin CyA formulation due apparent lack drug penetration study first vitro kinetic data CyA penetration human cadaver stratum corneum addition penetration enhancers PE Azone propylene glycol CyA vehicle drug permeation skin barrier flow-through permeability cells w/v CyA Sandimmun CyA PE CyA PE olive oil donor chamber penetration rate mean SD receptor fluid CyA CyA PE vivo efficacy formulation guinea-pigs undergoing delayed-type hypersensitivity DTH reactions DNFB CyA time challenge daily skin reactions appropriate drug vehicles concentrations CyA PE significant inhibitory effect erythema response significant reductions T-cell infiltrates CyA significant reductions erythema CyA PE reduction number lymphocytes sites CyA PE vehicle-treated sites PE penetration non-immunosuppressive concentration CyA skin